Advertisement
AXON vs GMAB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and GMAB is a StrongBuy.
AXON's RSI Oscillator ascends from oversold territory
The RSI Oscillator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 56 cases where AXON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.166) is normal, around the industry mean (4.854). AXON has a moderately high P/E Ratio (167.854) as compared to the industry average of (16.403). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
Aroon Indicator for GMAB shows an upward move is likely
GMAB's Aroon Indicator triggered a bullish signal on October 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator showed a similar pattern. In 144 of the 211 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
GMAB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.129) is normal, around the industry mean (2.973). P/E Ratio (31.226) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AXON | GMAB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 70 | 100 | |
SMR RATING 1..100 | 81 | 59 | |
PRICE GROWTH RATING 1..100 | 63 | 37 | |
P/E GROWTH RATING 1..100 | 44 | 5 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (92) in the Biotechnology industry is in the same range as GMAB (93) in the null industry. This means that AXON’s stock grew similarly to GMAB’s over the last 12 months.
AXON's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that AXON’s stock grew similarly to GMAB’s over the last 12 months.
GMAB's SMR Rating (59) in the null industry is in the same range as AXON (81) in the Biotechnology industry. This means that GMAB’s stock grew similarly to AXON’s over the last 12 months.
GMAB's Price Growth Rating (37) in the null industry is in the same range as AXON (63) in the Biotechnology industry. This means that GMAB’s stock grew similarly to AXON’s over the last 12 months.
GMAB's P/E Growth Rating (5) in the null industry is somewhat better than the same rating for AXON (44) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | GMAB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 72% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 64% |
| Advances ODDS (%) | 1 day ago 74% | 1 day ago 64% |
| Declines ODDS (%) | 4 days ago 70% | 15 days ago 71% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while GMAB’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- GMAB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 3 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 2 bearish.
- GMAB’s TA Score: 3 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -0.62% price change this week, while GMAB (@Biotechnology) price change was +5.76% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.31%. For the same industry, the average monthly price growth was -17.03%, and the average quarterly price growth was -18.12%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
AXON is expected to report earnings on Nov 03, 2026.
GMAB is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Aerospace & Defense (-3.31% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GMAB and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To GMAB | 1D Price Change % | ||
|---|---|---|---|---|
| GMAB | 100% | +1.09% | ||
| AXON - GMAB | 47% Loosely correlated | +2.98% | ||
| PCVX - GMAB | 42% Loosely correlated | -0.60% | ||
| BCYC - GMAB | 41% Loosely correlated | +1.96% | ||
| RYTM - GMAB | 41% Loosely correlated | +2.57% | ||
| EXEL - GMAB | 40% Loosely correlated | +1.13% | ||
More | ||||